Treatment of Childhood B-cell Acute Lymphoblastic Leukemia

Front-line Treatment Approach

The National Comprehensive Cancer Network recommends that children with newly diagnosed B-cell ALL should receive risk-stratified multiagent chemotherapy consisting of induction, consolidation, and maintenance phases, with treatment preferably delivered at a specialized cancer center 1
Enroll in a clinical trial whenever possible as the preferred approach, according to the National Comprehensive Cancer Network 2, 3
Begin with multiagent induction chemotherapy typically including vincristine, corticosteroids, and asparaginase, with or without an anthracycline, as recommended by the National Comprehensive Cancer Network 1
Assess minimal residual disease (MRD) status after induction, which is the most important prognostic factor, according to the National Comprehensive Cancer Network 1, 4

For MRD-negative patients after induction, the National Comprehensive Cancer Network recommends continuing with risk-stratified consolidation chemotherapy 2, 3
For MRD-positive patients after induction, the National Comprehensive Cancer Network suggests undergoing intensified consolidation therapy 2, 3
If MRD remains persistently positive, consider blinatumomab or tisagenlecleucel (category 2B), as recommended by the National Comprehensive Cancer Network 2, 3

For Philadelphia Chromosome-Positive B-cell ALL, the National Comprehensive Cancer Network recommends combining intensive chemotherapy with tyrosine kinase inhibitors (TKIs) 2, 3, 5
Imatinib (340 mg/m²/day) or dasatinib added to chemotherapy achieves 3-year event-free survival rates of 80-86%, according to the National Comprehensive Cancer Network 3, 5
For Infant ALL (Age <12 months), treat with Interfant-based chemotherapy regimens that incorporate elements of both ALL and AML protocols, as recommended by the National Comprehensive Cancer Network 4, 6, 7

For patients achieving second complete remission (CR2), the National Comprehensive Cancer Network recommends continuing chemotherapy with maintenance therapy or proceeding to HCT based on relapse risk 2, 3, 5
If MRD-positive or relapse after prior HCT, consider blinatumomab, tisagenlecleucel, or inotuzumab ozogamicin prior to first or second HCT, as suggested by the National Comprehensive Cancer Network 2, 3, 5
Long-term remissions have been reported after tisagenlecleucel without subsequent HCT, with 3-year relapse-free survival of 52% and only 22% proceeding to HCT, according to the National Comprehensive Cancer Network 1, 9

Intensified intrathecal chemotherapy prevents CNS relapse and may protect against late bone marrow relapse, as recommended by the National Comprehensive Cancer Network 1, 9
Isolated extramedullary relapse (CNS or testicular) requires systemic therapy to prevent marrow relapse, according to the National Comprehensive Cancer Network 1, 9
Do not delay treatment at non-specialized centers, as the complexity of therapy necessitates treatment at specialized cancer centers with ALL expertise, as recommended by the National Comprehensive Cancer Network 1
Do not proceed to HCT with detectable MRD when possible, as additional therapy to achieve MRD negativity before HCT improves outcomes, according to the National Comprehensive Cancer Network 1, 10, 4, 9